Zimbabwe has rejected a major US health deal worth $367m (272 million pounds) spanning five years due to the United States' request for confidential information.
The decision was revealed after a internal memorandum dated December was leaked, which showed Head of State Emmerson Mnangagwa believed the deal was "skewed".
An official spokesperson has since stated that the United States was seeking health data for research and commercial gain but was unwilling to share the resulting advantages from any future treatments.
"We are forced to start the challenging and unfortunate task of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had donated more than $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for more negotiations to find a deal agreeable to all parties so the country's vital HIV treatment initiative can continue.
Wider Background
This rejection follows a similar case in Kenya, where a court blocked a related health funding agreement following concerns were raised about the safety of citizens' health data.
Since resuming the presidency recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had administered assistance for the US government, but Trump claimed its spending was "inefficient" and his administration was seeking government-to-government deals to boost openness and accountability.
As per statements, 16 nations in Africa have to date agreed to similar agreements, constituting over $18.3bn in committed funds.
Details of the Rejected Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership might have yielded extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving antiretroviral therapy through US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data indefinitely, with no equivalent assurance of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that provided information," Mangwana explained.
"In essence, our nation would supply the basic resources for scientific discovery with no certainty that the final treatments would be available to our citizens should a new pandemic emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral health agreements were undermining frameworks previously established via the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing scheme created to deal with future pandemics.
"This mechanism is intended to ensure that when a nation contributes its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the capability to create them."
These objections regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We encourage continued discussions with our American counterparts on how future collaboration might be designed in a manner that respects the independence and dignity of each country."
Health Experts Response
Medical experts said it acknowledged the official position, but suggested that negotiations need to persist considering much of the country's HIV programmes relied on external financing.
"If technical issues exist, including those involving data governance or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," the group added.
The situation emphasises the ongoing debate between accepting much-needed foreign assistance and protecting a country's data in an increasingly data-driven world.